Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future

American Journal of Kidney Diseases

Volumn 35, Issue 2, 2000, Pages 333-346

  De Mattos, Angelo M ^a   Olyaei, Ali J ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cyclosporine; Graft rejection; Immunosuppression; Mycophenolate mofetil; Nephrotoxicity; Renal function; Tacrolimus

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

AUTOIMMUNE DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH CARE COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; REVIEW;

EID: 0033979599     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(00)70348-9     Document Type: Review

References (98)

1. B Zanker H Schneeberger U Rothenpieler G Hillebrand W Illner I Theodorakis M Stangl W Land Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: First 3-months analysis of efficacy and safety in two cohorts of renal allograft recipients Transplantation 66 1998 44 49
2. RM Graham Cyclosporine: Mechanisms of action and toxicity Cleve Clin J Med 61 1994 308 313
3. DH Peters A Fitton GL Plosker D: Faulds Tacrolimus A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation Drugs 46 1993 764 794
4. PI Terasaki JM Cecko Y Cho Overview PI Terasaki Clinical Transplants 1990 1990 UCLA Tissue Typing Laboratory Los Angeles, CA 585
5. D Cook Long-term survival of kidney allografts PI Terasaki Clinical Transplantation 1987 UCLA Tissue Typing Laboratory Los Angeles, CA 277
6. G Opelz V Schwarz A Engelmann D Back M Wilk E Keppel Long-term impact on kidney graft survival in cyclosporine-treated recipients Transplant Proc 23 1991 373 375
7. WM Bennett A de Mattos MM Meyer T Andoh JM Barry Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy Kidney Int 50 1996 1089 1100
8. K Solez F Vincenti R Filo U.S. FK506 Kidney Transplant Study Group: Prevalence of chronic allograft nephropathy and analysis of predictive factors: Results of 2-year protocol biopsies from a U.S. multicenter study Transplantation 65 suppl; abstr 15 1998 S82A
9. ME Cardenas D Zhu J Heitman Molecular mechanisms of immunosuppression by cyclosporine, FK506, and rapamycin Curr Opin Nephrol Hypertens 4 1995 472 477
10. SL Schreiber GR Crabtree The mechanism of action of cyclosporin A and FK506 Immunol Today 13 1992 136 142
11. TR Brazelton RE Morris Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506); sirolimus (rapamycin), mycophenolate mofetil and leflunomide Curr Opin Immunol 8 1996 710 720
12. T Ochiai Y Gunji M Nagata A Komori T Asano K Isono Effects of rapamycin in experimental organ allografting Transplantation 56 1993 15 19
13. WD Simmons SC Rayhill HW Sollinger Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection Drug Safety 17 1997 75 92
14. AC Allison EM Eugui The design and development of an immunosuppressive drug, mycophenolate mofetil Springer Semin Immunopathol 14 1993 353 380
15. U Christians K-F Sewing Cyclosporine metabolism in transplant patients Pharmacol Ther 57 1993 291 345
16. J Mason Pharmacology of cyclosporine (Sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals Pharmacol Rev 41 1990 423 434
17. A Asante-Korang GJ Boyle SA Webber SA Miller FJ Fricker Experience of FK506 immune suppression in pediatric heart transplantation: A study of long-term adverse effects J Heart Lung Transplant 15 suppl 1996 S415 S422
18. J McCauley The nephrotoxicity of FK506 as compared with cyclosporine Curr Opin Nephrol Hypertens 2 1993 662 669
19. CM Spencer KL Goa JC Gillis Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation Drugs 54 1997 925 975
20. PH Whiting J Woo BJ Adam NU Hasan RJL Davidson AW Thomson Toxicity of rapamycin: A comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat Transplantation 52 1991 203 208
21. MG Murgia S Jordan BD Kahan The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone–treated renal transplant patients Kidney Int 49 1996 209 216
22. C-C Chan DF Martin D Xu FG Roberge Side effects of rapamycin in the rat J Ocul Pharmacol Ther 11 1995 177 181
23. JF DiJoseph MJ Mihatsch SN Sehgal Renal effects of rapamycin in the spontaneously hypertensive rat Transpl Int 7 1994 83 88
24. US Multicenter FK506 Liver Study Group A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation N Engl J Med 331 1994 1110 1115
25. JJ Curtis RG Luke E Dubovsky AG Diethelm JD Whelchel P Jones Cyclosporine in therapeutic doses increases renal allograft vascular resistance Lancet 2 1986 477 479
26. FT Nielsen PP Leyssac E Kemp Starklint H Dieperink Nephrotoxicity of FK506 in the rat: Studies on glomerular and tubular function and on the relationship between efficacy and toxicity Nephrol Dial Transplant 10 1995 334 340
27. TF Andoh EA Burdmann J Lindsley DC Houghton WM Bennett Functional and structural characteristics of experimental FK 506 nephrotoxicity Clin Exp Pharmacol Physiol 22 1995 646 654
28. JB Kopp PE Klotman Cellular and molecular mechanisms of cyclosporin nephrotoxicity J Am Soc Nephrol 1 1990 162 179
29. MK Porayko SC Textor RAF Krom JE Hay GJ Gores TM Richards PH Crotty SJ Beaver JL Steers RH Wiesner Nephrotoxic effects of primary immunosuppression with FK506 and cyclosporine regimens after liver transplantation Mayo Clin Proc 69 1994 105 111
30. Y Kokado S Takahara M Kyo N Ichimaru W Jing-Ding T Miki A Okuyama Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation Transpl Int 11 suppl 1 1998 S60 S64
31. MJ Mihatsch B Ryffel F Gudat The differential diagnosis between rejection and cyclosporine toxicity Kidney Int 48 suppl 1995 S63 S69
32. BA Young EA Burdmann RJ Johnson CE Alpers CM Giachelli E Eng T Andoh WM Bennett WG Couser Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity Kidney Int 48 1995 439 448
33. DH Van Buren JF Burke RM Lewis Renal function in patients receiving long-term cyclosporine therapy J Am Soc Nephrol 4 suppl 1994 S17 S22
34. DJ Goldstein N Zeuch V Sehgal AD Weinberg R Drusin D Cohen Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression Transplantation 63 1997 664 668
35. ME Falkenhain FG Cosio DD Sedmak Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine Transplantation 62 1996 364 370
36. JG O'Grady A Forbes K Rolles RY Calne R Williams An analysis of cyclosporine efficacy and toxicity after liver transplantation Transplantation 45 1988 575 579
37. BD Myers R Sibley L Newton SJ Tomlanovich C Boshkos E Stinson JA Luetscher DJ Whitney D Krasny NS Coplon The long-term course of cyclosporine associated chronic nephropathy Kidney Int 33 1988 590 600
38. A Dieterle A Gratwohl H Nizze B Huser MJ Mihatsch G Thiel A Tichelli E Signer C Nissen B Speck Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients Transplantation 49 1990 1093 1110
39. JS Zaltzman Y Pei J Maurer A Patterson DC Cattran Cyclosporine nephrotoxicity in lung transplant recipients Transplantation 54 1992 875 878
40. International Kidney Biopsy Registry of Cyclosporine Sandimmune in Autoimmune Diseases Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients Br J Rheumatol 32 suppl 1 1993 S65 S71
41. J Hornberger J Best J Geppert M McClellan Risks and costs of end-stage renal disease after heart transplantation Transplantation 66 1998 1763 1770
42. MJ Mihatsch K Steiner KH Abeywickrama J Landmann G Thiel Risk factors for the development of chronic cyclosporine-nephrotoxicity Clin Nephrol 29 1988 165 175
43. P Ruiz PC Kolbeck MW Scroggs F Sanfilippo Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies Transplantation 45 1988 91 95
44. T Lyson D Ermel LeAnn PJ Belshaw DG Alberg SL Schreiber RG Victor Cyclosporine-and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling 73 1993 596 602
45. M Sander RG Victor Hypertension after cardiac transplantation: Pathophysiology and management Curr Opin Nephrol Hypertens 4 1995 443 451
46. M Sander T Lyson GD Thomas RG Victor Sympathetic neural mechanisms of cyclosporine-induced hypertension Am J Hypertens 9 suppl 1996 S121 S138
47. BM Murray MS Paller Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats Clin Nephrol 25 suppl 1986 S37 S39
48. MC Churchill PC Churchill AK Bidani The effects of cyclosporine in Lewis rats with native and transplanted kidneys Transplantation 55 1993 1256 1260
49. JM Wyss MS Mozaffari PL St John DR Abrahamson Cyclosporine-induced nephrotoxicity in deoxycorticosterone-NaCl treated rats Int J Exp Pathol 74 1993 615 626
50. M Carrier F Tronc D Stewart LC Pelletier Dose-dependent effect of cyclosporin on renal arterial resistance in dogs Am J Physiol 261 1991 H1791 H1796
51. G Mourad C Vela J Ribstein A Mimran Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy Transplantation 65 1998 661 667
52. T Bertani P Ferrazzi A Schieppati P Ruggenenti A Gamba L Parenzan G Mecca N Perico O Imberti A Remuzzi Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients Kidney Int 40 1991 243 250
53. RW Gruessner GW Burke R Stratta H Sollinger E Benedetti C Marsh P Stock JP Boudreaux M Martin MB Drangstveit DE Sutherland A Gruessner A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation Transplantation 61 1996 261 273
54. AD Mayer J Dmitrewski JP Squifflet T Besse B Grabensee B Klein FW Eigler U Heemann R Pichlmayr M Behrend Y Vanrenterghem J Donck J van Hooff M Christiaans JM Morales A Andres RW Johnson C Short B Buchholz N Rehmert W Land S Schleibner JL Forsythe D Talbot E Pohanka Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group Transplantation 64 1997 436 443
55. K-P Platz AR Mueller G Blumhardt S Bachmann WO Bechstein A Kahl P Neuhaus Nephrotoxicity following orthotopic liver transplantation: A comparison between cyclosporine and FK506 Transplantation 58 1994 170 178
56. G Remuzzi N Perico Cyclosporine-induced renal dysfunction in experimental animals and humans Kidney Int 48 suppl 52 1995 S70 S74
57. EA Ross A Wilkinson RA Hawkins GM Danovitch The plasma creatinine concentration is not an accurate reflection of the glomerular filtration rate in stable renal transplant patients receiving cyclosporine Am J Kidney Dis 10 1987 113 117
58. GM Danovitch Handbook of Kidney Transplantation 1996 Little, Brown New York, NY
59. AM Tegzess BM Doorenbos JM Minderhoud AJM Donker Prospective serial renal function studies in patients with nonrenal disease treated with cyclosporin A Transplant Proc 20 suppl 3 1988 S530 S533
60. D Ludwin I Alexopoulou Cyclosporin A nephropathy in patients with rheumatoid arthritis Br J Rheumatol 32 suppl 1 1993 S60 S64
61. RBM Landewé BAC Dijkmans FJ van der Woude FC Breedveld MJ Mihatsch JA Bruijn Long-term low-dose cyclosporine in patients with rheumatoid arthritis: Renal function loss without structural nephropathy J Rheumatol 23 1996 61 64
62. A Lindholm R Dahlqvist GG Groth F Sjöqvist A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation Br J Clin Pharmacol 30 1990 443 452
63. S Hedayat RP Kershner G Su Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants J Biopharm Stat 6 1996 411 424
64. H Akagi A Reynolds M Hjelm Cyclosporin A and its metabolites, distribution in blood and tissues J Int Med Res 19 1991 1 18
65. KD Lake DM Canafax Important interactions of drugs with immunosuppressive agents used in transplant recipients J Antimicrob Chemother 36 suppl B 1995 S11 S22
66. P Ruggenenti N Perico L Mosconi F Gaspari A Benigni CS Amuchastegui I Bruzzi G Remuzzi Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion Kidney Int 43 1993 706 711
67. K Ahmed B Michael JF Burke Jr Effects of isradipine on renal hemodynamics in renal transplant patients treated with cyclosporine Clin Nephrol 48 1997 307 310
68. M Epstein Calcium antagonists and renal protection: Current status and future perspectives Arch Intern Med 152 1992 1573 1584
69. JP Bantle MS Paller RJ Boudreau MT Olivari TF Ferris Long-term effects of cyclosporine on renal function in organ transplant recipients J Lab Clin Med 115 1990 233 240
70. AA Grace MA Barradas DP Mikhialioias JY Jeremy JF Moorhead P Sweny P Dandona Cyclosporin A enhances platelet aggregation Kidney Int 32 1987 889 895
71. PS Almond A Matas K Gillingham DL Dunn WD Payne P Gores R Gruessner JS Najarian Risk factors for chronic rejection in renal allograft recipients Transplantation 55 1993 752 756
72. C Hiesse N Neyrat A Deglise-Favre O Lantz H Bensadoun G Benoit B Charpentier D Fries Randomized prospective trial of elective cyclosporine withdrawal from triple therapy at 6 months after cadaveric renal transplantation Transplant Proc 23 1991 987 989
73. AA Hollander JL van Saase AM Kootte WT van Dorp HJ van Bockel LA van Es FJ van der Woude Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation Lancet 345 1995 610 614
74. IA MacPhee JA Bradley JD Briggs BJ Junor SG MacPherson MA McMillan RS Rodger MA Watson Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation Transplantation 66 1998 1186 1192
75. J Miller for the FK506/MMF Dose-Ranging Kidney Transplant Study Group Tacrolimus and mycophenolate mofetil in renal transplant recipients: Six and twelve month results of a multicenter, randomized dose ranging study Transplantation 65 1998 S266A (suppl; abstr 752)
76. MD Vu S Qi D Xu J Wu WE Fitzsimmons SN Sehgal L Dumont S Busque P Daloze H Chen Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat Transplantation 64 1997 1853 1856
77. C Mignat Clinically significant drug interactions with new immunosuppressive agents Drug Safety 16 1997 267 278
78. rd International Conference on New Trends in Clinical and Experimental Immunosuppression 1998 February Geneva, Switzerland 12 15
79. RGL de Sévaux PJH Smak Gregoor RJ Hené W Weimar AJ Hoitsma T van Gelder LB Hilbrands A randomised study of conventional vs low dose cyclosporine in renal transplant recipients treated with cyclosporine, mycophenolate mofetil and prednisone Transplantation 65 suppl 1 1998 S183A abstr 418
80. T van Gelder P de Kuiper NM van Besouw B van der Mast PJH Smak Gregoor JNM Ijzermans W Weimar Randomised trial comparing conversion of maintenance treatment with cyclosporine and prednisone to azathioprine or mycophenolate mofetil with prednisone one year after kidney transplantation Transplantation 65 suppl 1 1998 S140A abstr 248
81. D Abramowicz D Manas M Lao Y Vanrenterghem D del Castillo D Barker Preliminary results of a randomized, controlled study investigating the withdrawal of Neoral in stable renal transplant recipients receiving mycophenolate mofetil in addition to Neoral and steroids Transplantation 67 suppl 1 1999 S240A abstr 934
82. M Hueso J Bover D Seron S Gil-Vernet I Sabate X Fulladosa R Ramos O Coll J Alsina JM Grinyo Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function Transplantation 66 1998 1727 1731
83. JI Herrero J Quiroga B Sangro M Girala A Beltran R Rios F Pardo JA Cienfuegos J Prieto Conversion from cyclosporin A to mycophenolate mofetil in liver transplantation recipients with renal function impairment Transplantation 65 suppl 1 1998 S127A abstr
84. DE Eckhoff BM McGuire LR Frenette JL Contreras SL Hudson JS Bynon Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation Transplantation 65 1998 180 187
85. F Vincenti E Ramos B Nashan F Stuart Y Vanrenterghem C Brattstrom S Cho H Ekberg R Johnson J Grinyo Preliminary results of the combined use of a humanized anti-IL-2Rα monoclonal antibody, daclizumab (DZB) and mycophenolate mofetil (MMF) without calcineurin inhibitors in renal transplantation Transplantation 65 suppl 1 1998 S266A abstr 750
86. M Weir L Anderson JC Fink K Gabregiorgish EJ Schweitzer E Hoehn-Saric DK Klassen CB Cangro LB Johnson PC Kuo JY Lim ST Bartlett A novel approach to the treatment of chronic allograft nephropathy Transplantation 64 1997 1706 1710
87. D Ducloux V Founier C Bresson-Vautrin JM Rebibou C Billerey Y Saint-Hillier JM Chalopin Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: A preliminary report Transplantation 65 1998 1504 1506
88. L Houde P Noël R de Cotret D Boucher JG Lachance Prednisone-mycophenolate mofetil double therapy for cyclosporin A toxicity in kidney transplantation Transplantation 65 suppl 1 1998 S139A abstr 243
89. 1997 Annual Report of the US Scientific Registry for Transplant Recipients and the Organ Procurement and Transplantation Network—Transplant Data: 1998-1996. UNOS, Richmond, VA, and the Division of Transplantation, Office of Special Programs, Health Resources and Services Administration, US Department of Health and Human Services, Rockville, MD
90. US Renal Data System USRDS 1997 Annual Report. The National Institutes of Health, National Institute of Diabeties and Digestive and Kidney Diseases Am J Kidney Dis 30 suppl 1 1997 S54 S66
91. J Showstack P Katz W Amend O Salvatierra The association of cyclosporine with the 1-year costs of cadaver-donor kidney transplants JAMA 264 1990 1818 1823
92. GT Everson R Shrestha T Trouillot B Bilir A Amponsah M Wachs M Stegall G Mandell J Katz T Steinberg C Morgan B Fey C Ray I Kam Costs of cyclosporine (Neoral®) and tacrolimus (Prograf®) in the first year after liver transplantation (OLT) Transplantation 65 suppl 1; abstr 1998 S127A
93. B Ivanji H Fahmy P Szenohradszky H Hansen S Olsen P Halloran K Solez Multilamellation of the peritubular capillary basement membrane in chronic renal allograft rejection 24th Annual Scientific Meeting of the American Society of Transplant Surgeons 1998 171A (abstr)
94. CF Shield III RJ Jacobs S Wyant A Das A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation Am J Kidney Dis 27 1996 855 864
95. AJ Matas VA Tellis T Quinn G Karwa D Glichlick R Soberman F Veith Treatment of renal transplant rejection episodes in patients receiving prednisone and azathioprine. A cost-effective approach Transplantation 40 1985 35 39
96. MH Deierhoi S Gupta SL Hudson RS Gaston AG Diethelm 24th Annual Scientific Meeting of the American Society of Transplant Surgeons Cost considerations and the use of mycophenolate mofetil in renal transplantation 19A 1998 (abstr)
97. GM Baker JE Martin R Jang SA Myre JA Armistead TJ Schroeder Pharmacokinetic analysis of mycophenolate mofetil versus azathioprine in cadaveric renal transplantation Transplantation 65 suppl 1 1998 S132A abstr
98. C Louis-Touizer MJ Nuijten F Bayle D Cantarovich P Lang Y Lebranchu P Le Pogamp JL Touraine P Vialtel T Monroe MJ de Vries Economic contribution of mycophenolate mofetil as preventive immunosuppressive treatment after renal transplantation from cadaver [in French] Presse Med 25 1996 1577 1582